ESMO 2022 | Mechanism of action for air pollution-induced NSCLC

Charles Swanton, FRCP, BSc, PhD, Francis Crick Institute, London, UK, discusses the role of the air pollutant, particulate matter, in the development of non-small cell lung cancer (NSCLC) in never-smokers, as evaluated in the TRACERx trial (NCT01888601). In England, South Korea and Taiwan, increasing particulate matter levels were associated with increased risk of EGFR mutant NSCLC, providing evidence to limit air pollution and opportunities for molecular targeted cancer prevention. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.